Morvarid Mohseni, Ph.D
Affiliations: | 2009-2013 | Stem Cell & Regenerative Biology | Harvard - Boston Children's Hospital |
Area:
Cell Biology, Oncology, Regenerative Biology, Molecular Pharmacology, Stem Cell Biology,Google:
"Morvarid Mohseni"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Athar Chishti | grad student | 2009 | University of Illinois, Chicago |
| Fernando Camargo | post-doc | 2013 | Harvard - Boston Children's Hospital |
Collaborators
Sign in to add collaborator| Adam Bass | collaborator | ||
| Stephen C. Blacklow | collaborator | (Chemistry Tree) | |
| Reuben Kapur | collaborator | (Cell Biology Tree) | |
| Keith L. Ligon | collaborator | ||
| Scott R. Manalis | collaborator | (E-Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Amante RJ, Jehanno C, De Silva D, et al. (2023) PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Journal of Mammary Gland Biology and Neoplasia. 28: 13 |
| Vemulapalli V, Chylek LA, Erickson A, et al. (2021) Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. Elife. 10 |
| Wang Y, Mohseni M, Grauel A, et al. (2021) SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Scientific Reports. 11: 1399 |
| Hao HX, Liu C, Lu H, et al. (2020) Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| LaMarche MJ, Acker MG, Argintaru A, et al. (2020) Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry |
| Lu H, Liu C, Huynh H, et al. (2020) Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget. 11: 265-281 |
| Pandey R, Ramdas B, Wan C, et al. (2019) SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. The Journal of Clinical Investigation |
| Hao HX, Wang H, Liu C, et al. (2019) Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers. Molecular Cancer Therapeutics |
| Lu H, Liu C, Velazquez R, et al. (2019) SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Molecular Cancer Therapeutics |
| Sarver P, Acker M, Bagdanoff JT, et al. (2019) Correction to 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Journal of Medicinal Chemistry |